Monoamine oxidase activities in brown adipose tissue of the rat: Some properties and subcellular distribution

Amine oxidase activity towards 5-hydroxytryptamine (5HT), tyramine (TYR), 2-phenylethylamine (PEA) and benzylamine (BZ) was studied in homogenates of interscapular brown adipose tissue of the rat. By the use of clorgyline, an irreversible inhibitor of MAO, it was established that 5HT was deaminated solely by MAO-A, and TYR and PEA mainly by MAO-A and clorgyline-resistant semicarbazide-sensitive amine oxidase (CRAO). BZ appeared to be oxidized almost entirely by CRAO. A very small amount of MAO-B activity was detectable with PEA and BZ as substrates. A variety of amines, amino acids and known amine oxidase inhibitors were tested for their ability to inhibit the deamination of BZ by CRAO. BZ metabolism by the enzyme was not affected by any secondary amines, unlike enzymes of the flavin type, but it was inhibited by carbonyl reagents, like the pyridoxal phosphate and copper-dependent amine oxidases described in plasma and connective tissue. Unlike these enzymes, however, CRAO in brown adipose tissue was resistant to KCN and unaffected by the amines, histamine, mescaline and some polyamines but it was inhibited by cuprizone. It was found to have a low K_m (<5 μM) for BZ and showed the greatest similarity to a clorgyline-resistant enzyme described in rat blood vessels. Cell fractionation studies revealed that CRAO, being associated with the particulate fractions, was mainly membrane-bound. The distribution of CRAO activity between various cell fractions was different from that of the mitochondrial enzymes assayed and was more like that of either the plasma membrane or microsomal enzymes. When microsomal and plasma membrane vesicles were separated CRAO activity appeared distributed equally between the two fractions, suggesting that the enzyme may have a dual location within the cell. The specific activity of CRAO was higher in brown adipose tissue from obese animals than in tissue from lean animals. The significance of these findings is discussed in relation to the possible physiological function of this enzyme.     

In vitro and in vivo inhibition by benserazide of clorgyline-resistant amine oxidases in rat cardiovascular tissues

Benserazide (d, l-serine 2-[2,3,4-trihydroxybenzyl]-hydrazide) has been shown to inhibit the clorgyline-resistant amine oxidase (CRAO) activities which metabolize benzylamine in homogenates of rat aorta, heart and brown adipose tissue. In vitro studies showed a concentration- and timedependent inhibition of CRAO in heart and aorta which was reversed by dialysis for 18hr. At high concentrations (10^?4?10^?3M) benserazide appeared to increase enzyme activity towards and occasionally above control value. These increases became more prominent after long periods of preincubation (especially in the presence of saturating benzylamine concentrations) and remained after dialysis of those homogenates preincubated with benserazide. The administration of benserazide for one or seven days in daily doses of 5–150 mg/kg also inhibited CRAO activity in vivo in a dose-dependent manner, with greater inhibition after seven days treatment. Reversal of inhibition, by dialysis of tissue homogenates from benserazide-treated rats, was much slower than was found with homogenates incubated in vitro with the drug. After benserazide administration to rats, MAO-A activity towards 5-hydroxytryptamine was generally not inhibited, and in fact was significantly increased in some cases. The administration of l-DOPA (250 mg/kg) together with benserazide (40 mg/kg) resulted in a similar degree of CRAO inhibition m aorta and heart to that seen after benserazide alone. These findings are discussed with regard to the use of these drugs in the therapy of Parkinson's Disease, although the paucity of information about the physiological function of CRAO makes the significance of its inhibition by benserazide unclear.     

Binding and deamination of various substrates by types A and B monoamine oxidase in bovine brain mitochondria

The binding and deamination of four substrates by type A and type B monoamine oxidase (MAO) in bovine brain mitochondria were investigated in mixed substrate experiments. MAO activity in bovine brain mitochondria, with 5-hydroxytryptamine (5-HT) as substrate, was highly sensitive to clorgyline and less sensitive to deprenyl, while MAO activity with benzylamine or β-phenylethylamine (PEA) as substrate was highly sensitive to deprenyl and less sensitive to clorgyline. On the other hand, when tyramine plus PEA was used as substrate, the inhibition curves of clorgyline and deprenyl were both biphasic. These results indicate that 5-HT and benzylamine were preferentially deaminated by type A MAO and type B MAO, respectively, and that tyramine and PEA were deaminated by both types of MAO. Studies on the inhibition by clorgyline plus deprenyl of tyramine deamination (in the absence and presence of another substrate) showed that the deamination of tyramine by both type A and type B MAO was inhibited by PEA or benzylamine, while only type A MAO was inhibited significantly by 5-HT. The KA_i value, the dissociation constant of the type A MAO and 5-HT complex, and the KB_i values, the dissociation constants of the type B MAO and PEA or benzylamine complex, were almost equal to the K_m values of type A MAO and type B MAO respectively. The KA_i values for PEA and benzylamine were 78 and 58 μM respectively. For the type B MAO-5-HT complex, the dissociation constant KB_i was 1447 μM. These results show that type A MAO deaminates tyramine and 5-HT whereas benzylamine is not deaminated, but only binds to the substrate binding site of type A MAO with almost the same rate as that for deamination by type B MAO; with type B MAO, tyramine, PEA and benzylamine are deaminated, whereas 5-HT is not deaminated and binds to the substrate binding site of type B MAO with low affinity.     

Characteristics and specificity of phenelzine and benserazide as inhibitors of benzylamine oxidase and monoamine oxidase

The selectivity of benserazide and phenelzine toward inhibition of benzylamine oxidase (BzAO) and monoamine oxidases (MAO-A and MAO-B) was studied in homogenates of rat skull and lung. In addition, the kinetic interaction and reversibility of BzAO inhibition were assessed. Both drugs inhibited BzAO but only phenelzine inhibited MAO, whether tested in vitro or in vivo. Neither compound acted as an irreversible inhibitor of BzAO. Benserazide was found to be a noncompetitive inhibitor. Phenelzine acted as a substrate for BzAO followed by product-induced noncompetitive inhibition which was labile at 37° but not at 4°. A reversible component in phenelzine-induced inhibition of MAO-A and -B is also suggested from in vivo studies.     

The deamination of n-pentylamine by monoamine oxidase and a semicarbazide-sensitive amine oxidase of rat heart

n-Pentylamine is deaminated by homogenates of rat heart. Clorgyline inhibition curves at 10 and 100 μM n-pentylamine indicated that this substrate was deaminated by MAO-A, -B and a clorgyline-resistant amine oxidase sensitive to inhibition by semicarbazide. These results have been compared with two other commonly used monoamine substrates, β-phenethylamine and benzylamine.     

Properties of a semicarbazide-sensitive amine oxidase in human umbilical artery

The metabolism of some aromatic amines by amine oxidase activities in human umbilical artery homogenates has been studied. The inhibitory effects of clorgyline showed that 5-hydroxytryptamine (5-HT) and tryptamine, 1 mM, were predominantly substrates for monoamine oxidase (MAO) type A, whereas MAO-A and B were both involved in the metabolism of beta-phenylethylamine (PEA), 100 microM, and tyramine, 1 mM. About 20-30% of tyramine and PEA metabolism was resistant to 1 mM clorgyline, but sensitive to inhibition by semicarbazide, 1 mM, indicating the presence of a semicarbazide-sensitive amine oxidase (SSAO). Benzylamine, 1 mM, appeared to be metabolized exclusively by SSAO with a Km (161 microM) at pH 7.8 similar to that found for SSAO in other human tissues. Tyramine and PEA were relatively poor substrates for SSAO, with very high apparent Km values of 17.6 and 13.3 mM, respectively, when determined in the presence of clorgyline, 10(-3) M, added to inhibit any metabolism of those amines by MAO activities. However, kinetic studies with benzylamine indicated that clorgyline, 10(-3) M, also appears to inhibit SSAO competitively such that the true Km values for tyramine and PEA may be about 60% of those apparent values given above. No evidence for the metabolism of 5-HT or tryptamine by SSAO was obtained. The aliphatic amine methylamine was recently shown to be a specific substrate for SSAO in umbilical artery homogenates. We have used benzylamine and methylamine as SSAO substrates in histochemical studies to localize SSAO in tissue sections.(ABSTRACT TRUNCATED AT 250 WORDS)     

Substrate and inhibitor selectivity of human heart monoamine oxidase.

The subcellular distribution, inhibitor sensitivity, thermostability and pH profiles of monoamine oxidase (MAO) from samples of human heart obtained at post mortem have been investigated with several substrates. A simple subcellular fractionation showed that, with either tyramine or benzylamine as substrate, about 50 per cent of the MAO activity was found in the mitochondrial fraction, with negligible quantities in the high speed supernatant. From the use of clorgyline, it appears that 5-HT is a substrate for MAO-A, benzylamine and β-phenethylamine are substrates for MAO-B, while tyramine and dopamine are substrates for both forms of the enzyme, d-Amphetamine was shown to be a selective competitive inhibitor of MAO-A, of similar potency to that observed with MAO from rat liver. No significant difference between the thermostability at 50° of the MAO activity towards 5-HT and benzylamine was observed. Preliminary results for the effect of pH on human heart MAO are presented. The results are discussed with respect to similar data obtained for MAO from other human and animal tissues.     

Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase

Human platelet monoamine oxidase (MAO) preferentially deaminated benzylamine and phenylethylamine, two substrates relatively specific for type B MAO, in comparison to 5-hydroxytryptamine, a substrate specific for type A MAO. In studies comparing human platelet and rat brain MAO specific activities, benzylamine and 5-hydroxytryptamine deamination by platelets was approximately 90 and 2 per cent, respectively, that of brain, while platelet deamination of dopamine, tryptamine and tyramine was 20 per cent or less than that of brain. Among sixteen drugs studied, platelet MAO activity was selectively inhibited by low concentrations of the MAO-B inhibitors, deprenyl and pargyline, and was relatively insensitive to the MAO-A inhibitors, clorgyline and Lilly 51641. These observations, in addition to the simple sigmoid inhibition curves obtained with increasing concentrations of either clorgyline or deprenyl, suggest that platelet MAO consists of essentially one distinguishable form of MAO which most closely resembles the MAO type B found in other tissues.     

p-Methoxyamphetamine,a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo

p-Methoxyamphetamine is over 20 times as potent as (+)-amphetamine as an inhibitor of 5-HT oxidation by monoamine oxidase in mouse brain in vitro, with a K_i value of 0·22 μM. It is highly selective towards A-type monoamine oxidase and possesses only weak activity against the B-type enzyme (Ki value about 500 μM with benzylamine as substrate and solubilized rat liver mitochondria as enzyme source). It is 10 times more active than (+)-amphetamine in protecting mouse brain monoamine oxidase from inhibition by phenelzine in vivo. o-Methoxy- and m-methoxyamphetamines inhibit monoamine oxidase both in vitro and in vivo with potencies comparable with, or less than that of (+)-amphetamine.     

Possible heterogeneity of type B monoamine oxidase in pig heart mitochondria

The metabolism in vitro of 5-hydroxytryptamine (5-HT), tyramine and benzylamine by pig heart mitochondrial monoamine oxidase (MAO) has been studied. Linear Lineweaver-Burk plots yielded estimated K_m values (at pH 7.8) of 475 μM (5-HT) and 292 μM (tyramine). In contrast, linear regions of a downward-curving reciprocal plot revealed the presence of a high- and low-affinity metabolizing site (estimated K_m of 39 and 853 μm respectively) for benzylamine. Studies with the irreversible MAO inhibitor clorgyline indicated that metabolism of the three substrates in this tissue was brought about by type B MAO alone. However, the apparent sensitivity toward clorgyline of each substrate-metabolizing activity was not identical. This was due to different degrees of rapid or possibly instantaneous inhibition of enzyme activity toward each substrate. This rapid inhibition appeared to be both partially reversible and irreversible to a relative degree depending upon the substrate-metabolizing activity studied; additional time-dependent inhibition developing with prolonged preincubation was a first-order process, with a similar half-life, whichever substrate was used to assay MAO activity. Ackermann-Potter and Lineweaver-Burk plots also demonstrated differences in the inhibitory effects of clorgyline upon metabolism of each substrate. The ability of 5-HT, tyramine and benzylamine to inhibit each other's deamination in vitro was also investigated. Enzyme activity was measured by radiochemical assay with each labeled substrate in the presence and absence of the other non-labeled amines. Lineweaver-Burk analysis revealed a competitive interaction between tyramine and benzylamine, whereas mixed-type inhibition patterns were obtained for mixtures containing 5-HT/tyramine or 5-HT/benzylamine. In this latter case, the present inhibition data could only be assessed accurately with the low-affinity catalytic site for benzylamine. The kinetics of heat denaturation indicated both a thermolabile and thermostable component of each substrate-metabolizing activity. Some substrate-dependent differences in the relative proportions of these components were found. These experiments are discussed in relation to similar studies by other workers and suggest that pig heart MAO may, in fact, be heterogeneous.     

Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain

Cortex and caudate specimens from human, non-human primate and rodent brains were examined for their ability to deaminate dopamine and for their sensitivity to irreversible monoamine oxidase (MAO) inhibitors. Using inhibition curves obtained with clorgyline, deprenyl and pargyline to estimate the relative proportions of MAO-A and MAO-B activity, dopamine was found to be deaminated predominantly by MAO-A in rat cortex and caudate. In contrast, dopamine was primarily an MAO-B substrate in human and vervet cortex and caudate. When clorgyline inhibition curves with tyramine or dopamine as substrate were compared in human, vervet and rat cortex, more pronounced species differences were found with dopamine than with tyramine. In all three species caudate tended to be more sensitive to inhibition by low concentrations of clorgyline than was cortex, suggesting a higher proportion of MAO-A activity in caudate. Similar species differences were also found when MAO-A activities were estimated using serotonin (5-HT): -phenylethylamine (PEA) ratios (5-HT/5-HT + PEA). These ratios with selective substrates were highly correlated with clorgyline inhibition curves obtained with tyramine as substrate across 29 brain regions and tissues from different rodent and primate species (r=0.85, P<0.001). Data from both the substrate ratios and the clorgyline inhibition curves confirmed the relative predominance of MAO-B activity in primate brain regions (70–85%) as compared to rat brain regions (45%). Smaller species differences were observed in liver. Species differences in the proportion of brain MAO-A and B activities and in the deamination of dopamine and other substrates for MAO may have important implications in regard to the widespread use of rodent rather than primate models in the study of biogenic amine metabolism and of drugs affecting amine function.     

A new approach to the assessment of the potency of reversible monoamine oxidase inhibitors in vivo, and its application to (+)- amphetamine, p-methoxy amphetamine and harmaline

A new kinetic formulation for the interaction between reversible and irreversible enzyme inhibitors has been used as a basis for determining enzyme active centre occupancy by reversible enzyme inhibitors in vitro. This formulation has been validated in vitro by comparing the monoamine oxidase active centre occupancy by ( + )-amphetamine calculated from its ability to reduce inhibition by phenelzine with that calculated from its direct inhibitory action on the enzyme. From studies on the protection afforded against inhibition of mouse brain monoamine oxidase by phenelzine in vitro. I₅₀ values of 5, 0.5 and 0.1 mg·kg^?1 have been obtained for the inhibition of this enzyme by ( + )-amphetamine, p-methoxyamphetamine and harmaline. The protection afforded by amphetamine and p-methoxyamphetamine against inhibition by pheniprazine, clorgyline and tranylcypromine has also been studied.     

Tyramine infusions and selective monoamine oxidase inhibitor treatment

The relationship between changes in IV tyramine pressor sensitivity accompanying selective monoamine oxidase (MAO) inhibitor treatment and estimates of MAO-A and MAO-B inhibition in vivo were studied. Reductions in platelet MAO activity provided an index of MAO-B inhibition, while changes in plasma 3-methoxy-4-hydroxyphenethylene glycol (MHPG) were used as an hypothesized reflection of MAO-A inhibition. Chronic treatment with the MAO-A inhibitor clorgyline and the MAO-B inhibitor pargyline showed significant inhibition of the alternate MAO enzyme as well, although this crossover effect was greater for pargyline than clorgyline. The MAO-B inhibitor deprenyl appeared to maintain the greatest degree of MAO inhibition selectivity in vivo. Tyramine pressor sensitivity changes accompanying administration of the MAO inhibitors were highly correlated with decreases in plasma MHPG (r=0.92), supporting our previous data indicating the rank order of clorgyline > pargyline > deprenyl for enhancement of tyramine pressor sensitivity and, thus, suggesting that tyramin potentiation is primarily a function of MAO-A rather than MAO-B inhibition. Changes in plasma MHPG are suggested to provide a potentially useful clinical index of in vivo MAO-A inhibition.Presently with the Biological Psychiatry Branch, NIMH     

The effect of age and thyroid hormones upon the ability of the chick heart to deaminate monoamines

The effect of age and thyroid hormones upon the ability of chick heart homogenates to metabolize monoamines has been investigated. 5-Hydroxytryptamine is entirely metabolized by a monoamine oxidase (MAO) with the characteristics of MAO-A, whereas some of the tyramine and all of the benzylamine are oxidatively deaminated by a clorgyline-resistant, but semicarbazide-sensitive enzyme, with a similar subcellular distribution to that of MAO. The remainder of the tyramine deamination is brought about by MAO-A and MAO-B. The specific activities of both clorgyline-sensitive and resistant enzymes are increased by the same proportion by increase in age or by treatment with (-)-thyroxine, and decreased by 2-thiouracil. The significance of these results is discussed.     

The effect of age and thyroid hormones upon the ability of the chick heart to deaminate monoamines.

The effect of age and thyroid hormones upon the ability of chick heart homogenates to metabolize monoamines has been investigated. 5-Hydroxytryptamine is entirely metabolized by a monoamine oxidase (MAO) with the characteristics of MAO-A, whereas some of the tyramine and all of the benzylamine are oxidatively deaminated by a clorgyline-resistant, but semicarbazide-sensitive enzyme, with a similar subcellular distribution to that of MAO. The remainder of the tyramine deamination is brought about by MAO-A and MAO-B. The specific activities of both clorgyline-sensitive and resistant enzymes are increased by the same proportion by increase in age or by treatment with (--)-thyroxine, and decreased by 2-thiouracil. The significance of these results is discussed.     

Vascular smooth muscle cells: a major source of the semicarbazide-sensitive amine oxidase of the rat aorta

Several methods have been used to study the distribution of the semicarbazide-sensitive amine oxidase (SSAO) within the wall of the rat aorta. After separation of the smooth muscle-containing layers of the tunica media from the connective tissue of the tunica adventitia, much higher specific enzyme activity (measured with 1 microM benzylamine) was found in homogenates of the media than of adventitia. Similar results were obtained for MAO-A (with 1 mM 5-HT as substrate). SSAO activity was also considerably higher in homogenates of cells (predominantly smooth muscle) isolated from medial tissue by enzymatic dissociation with collagenase and elastase compared with homogenates of cells (mostly of connective tissue origin) from the adventitia. Histochemical staining resulting from SSAO activity (with benzylamine as substrate) occurred predominantly and intensely over the tunica media in rat aortic sections, although some occasional staining of adventitial sites was also observed. Staining was prevented by the SSAO inhibitors hydroxylamine (1 microM) and semicarbazide (1 mM), but not by the MAO inhibitor, clorgyline (1 mM). These results indicate that SSAO is associated predominantly, although not exclusively, with the smooth muscle cells in the rat aorta. Our findings that beta-aminopropionitrile (BAPN) is a reversible, competitive inhibitor (Ki around 2 X 10(-4)M) of SSAO, in contrast to the irreversible inhibition of the connective tissue lysyl oxidase by BAPN reported by others, provides further evidence that these enzymes are not identical.     

Some factors influencing the metabolism of benzylamine by type A and B monoamine oxidase in rat heart and liver

The ability of MAO-A and MAO-B to metabolize benzylamine in vitro has been investigated in mitochondrial preparations from rat liver and heart. Although under normal circumstances benzylamine appeared to be metabolized exclusively by MAO-B in the rat liver, a contribution by both MAO-A and a clorgyline-resistant enzyme component was revealed when the MAO-B activity was much reduced by pretreatment of the mitochondria with appropriate concentrations of deprenyl. These three enzyme activities also contributed to benzylamine deamination in rat heart mitochondria. However, binding studies with [³ H]pargyline, which provided an estimate of the respective concentrations of MAO-A and MAO-B active centres in heart mitochondria, indicated a ratio between MAO-A and MAO-B, markedly different from that shown by plots of inhibition of benzylamine metabolism by various concentrations of clorgyline. The interpretation of these clorgyline plots is discussed in terms of the kinetic constants of both MAO-A and MAO-B, and the relative amounts of each enzyme. It is proposed that although the turnover rate constant for benzylamine metabolism by MAO-A is much smaller than that shown by MAO-B, in those tissues containing a large ratio of MAO-A:MAO-B content, the metabolism of benzylamine by MAO-A can be detected.     

Monoamine oxidase in rat arteries: Evidence for different forms and selective localization

1. Two forms of monoamine oxidase activity were differentiated in rat mesenteric and femoral artery by means of substrate and inhibitor specificities: one form deaminated tyramine, 5-hydroxytryptamine and noradrenaline and was highly sensitive to pargyline and clorgyline but resistant towards carbonyl reagents. This form resembled type A monoamine oxidase previously described. The other deaminated tyramine but not 5-hydroxytryptamine or noradrenaline and was inhibited by carbonyl reagents but not by clorgyline or pargyline.

2. About one third of the total monoamine oxidase in homogenates of rat mesenteric artery was recovered in a 10⁵ g supernatant. Both forms were partially soluble, but relatively less of the type A activity was recovered in the soluble fraction.

3. Chemical sympathectomy with 6-hydroxydopamine resulted in a loss of 59% of monoamine oxidase activity in the mesenteric artery. There was a selective loss of type A activity, as revealed by the 70% decrease in 5-hydroxytryptamine deaminating ability and by the marked decrease in clorgyline sensitivity. The second monoamine oxidase species was resistant to 6-hydroxydopamine. The soluble activity was not affected by chemical sympathectomy. Most of the transmitter-specific monoamine oxidase of the arterial wall was localized within the adrenergic nerve endings. Our observations are consistent with the hypothesis that extraneuronal monoamine oxidase plays only a minor role in metabolizing noradrenaline in sympathetically innervated tissues.

4. Plasma amine oxidase might originate from the arterial wall since it has similar characteristics to that found in the mesenteric artery.

     

Monoamine oxidase activities of dissociated cell fractions from rat ventricular muscle

Cell fractions enriched in cardiac muscle cells (myocytes), on the one hand, and in non-myocytes, on the other, were prepared by dissociation of rat ventricular tissue with collagenase. Amine oxidase activities in homogenates of these cell fractions and also in homogenates of the corresponding undissociated ventricular tissue were compared. In addition, the activity of alkaline phosphatase (AP), an enzyme found predominantly associated in the heart with non-myocytes, particularly capillary endothelial cells, was also measured. No significant difference in the activity of MAO-A (assayed with 1 mM 5-hydroxytryptamine) was found between myocyte and non-myocyte fractions. In contrast, the activities of alkaline phosphatase (AP) and also the semicarbazide-sensitive amine oxidase (SSAO), assayed with 1 microM benzylamine (BZ), were both significantly higher in non-myocytes, by several-fold, than in myocyte fractions. Studies of the inhibition by clorgyline of 1 mM BZ metabolism confirmed that both MAO-A and MAO-B can also contribute to BZ oxidation in the rat heart. These experiments indicated different ratios of MAO-A: MAO-B in the various cell fractions. The ratios of the percentage contributions of MAO-A and MAO-B, respectively, to the total metabolism of 1 mM BZ were 78:20 (myocytes), 43:52 (non-myocytes) and 57:32 (undissociated tissue). These results suggest that MAO-B, in addition to AP and SSAO, may be associated preferentially with non-myocyte constituents of the rat heart. Although cardiac myocytes appear to contain predominantly MAO-A, this enzyme form is also localized, with high activity, to the non-myocyte fraction. However, since the non-myocyte fraction is heterogeneous in its cell content, containing vascular components of the coronary microcirculation, as well as other cells of connective tissue origin, the exact cellular localization of the enzyme activities within this fraction has not yet been defined.     

MAO types in guinea pig liver mitochondria

MAO of guinea pig liver mitochondria actively deaminated dopamine, tyramine, serotonin and 5-methoxy-tryptamine, while tryptamine, 5-methyl-tryptamine and 7-methyl-tryptamine were moderately deaminated. Very little deamination occurred when benzylamine. noradrenaline and β-phenylethylamine were used as substrates. The in vitro inhibition patterns of MAO of guinea pig liver mitochondria by some selective inhibitors were investigated in the presence of tyramine, tryptamine and serotonin. Tryptamine oxidation showed biphasic inhibition pattern with harmaline, clorgyline and Lilly 51641, while the inhibition curves in the presence of pargyline and deprenyl were sigmoidal. The inhibition curves for tyramine oxidation were biphasic with all the inhibitors except pargyline. Serotonin-MAO inhibition curves, on the other hand, were sigmoidal with all the inhibitors except Lilly 51641. Thermal treatment of guinea pig liver mitochondria produced rapid inactivation of serotonin and tryptamine oxidizing activity, while benzylamine oxidizing activity was found to be most thermostable.